Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020.

Kazia, believes that the best thing they can do for thei investors is to deliver high-quality science that makes a substantial impact on the lives of patients.

Value Proposition for Investors

Kazia’s pipeline assets are scientifically well-validated, and their early development has been performed to the highest possible standards of quality in large pharmaceutical companies.

The company has a track record of successful partnering, both inbound and outbound and has demonstrated the ability to realise value from its pipeline, even prior to product approval.

Kazia is a lean, agile business, in which broad clinical trial programs have been deployed with a very high level of cost efficiency, and which has shown a consistent ability to deliver on its objectives.

The Kazia team are distinguished by deep experience in drug development, empowered by a commitment to high-quality service, and inspired by a passion for making a difference in the lives of patients.